159 related articles for article (PubMed ID: 29179431)
1. Sleeping through the storm: Preventing myelosuppression with quizartinib.
Taylor SJ; Langdon WY
Oncotarget; 2017 Oct; 8(51):88255-88256. PubMed ID: 29179431
[No Abstract] [Full Text] [Related]
2. Hitting the snooze button: Inducing quiescence with the FLT3 inhibitor quizartinib protects hematopoietic progenitors from chemotherapy.
Taylor SJ; Langdon WY
Mol Cell Oncol; 2017; 4(6):e1378156. PubMed ID: 29209657
[TBL] [Abstract][Full Text] [Related]
3. Preventing chemotherapy-induced myelosuppression by repurposing the FLT3 inhibitor quizartinib.
Taylor SJ; Duyvestyn JM; Dagger SA; Dishington EJ; Rinaldi CA; Dovey OM; Vassiliou GS; Grove CS; Langdon WY
Sci Transl Med; 2017 Aug; 9(402):. PubMed ID: 28794285
[TBL] [Abstract][Full Text] [Related]
4. Clinical Outcomes in Patients with FLT3-ITD-Mutated Relapsed/Refractory Acute Myelogenous Leukemia Undergoing Hematopoietic Stem Cell Transplantation after Quizartinib or Salvage Chemotherapy in the QuANTUM-R Trial.
Ganguly S; Cortes JE; Krämer A; Levis MJ; Martinelli G; Perl AE; Russell NH; Arunachalam M; Santos CD; Gammon G; Lesegretain A; Mires DE; Pham H; Wang Y; Khaled SK
Transplant Cell Ther; 2021 Feb; 27(2):153-162. PubMed ID: 33017662
[TBL] [Abstract][Full Text] [Related]
5. Hematopoietic niche drives FLT3-ITD acute myeloid leukemia resistance to quizartinib
Dumas PY; Naudin C; Martin-Lannerée S; Izac B; Casetti L; Mansier O; Rousseau B; Artus A; Dufossée M; Giese A; Dubus P; Pigneux A; Praloran V; Bidet A; Villacreces A; Guitart A; Milpied N; Kosmider O; Vigon I; Desplat V; Dusanter-Fourt I; Pasquet JM
Haematologica; 2019 Oct; 104(10):2017-2027. PubMed ID: 30923103
[TBL] [Abstract][Full Text] [Related]
6. Quizartinib (AC220): a promising option for acute myeloid leukemia.
Zhou F; Ge Z; Chen B
Drug Des Devel Ther; 2019; 13():1117-1125. PubMed ID: 31114157
[TBL] [Abstract][Full Text] [Related]
7. Quizartinib versus salvage chemotherapy in relapsed or refractory FLT3-ITD acute myeloid leukaemia (QuANTUM-R): a multicentre, randomised, controlled, open-label, phase 3 trial.
Cortes JE; Khaled S; Martinelli G; Perl AE; Ganguly S; Russell N; Krämer A; Dombret H; Hogge D; Jonas BA; Leung AY; Mehta P; Montesinos P; Radsak M; Sica S; Arunachalam M; Holmes M; Kobayashi K; Namuyinga R; Ge N; Yver A; Zhang Y; Levis MJ
Lancet Oncol; 2019 Jul; 20(7):984-997. PubMed ID: 31175001
[TBL] [Abstract][Full Text] [Related]
8. Quizartinib plus chemotherapy in newly diagnosed patients with FLT3-internal-tandem-duplication-positive acute myeloid leukaemia (QuANTUM-First): a randomised, double-blind, placebo-controlled, phase 3 trial.
Erba HP; Montesinos P; Kim HJ; Patkowska E; Vrhovac R; Žák P; Wang PN; Mitov T; Hanyok J; Kamel YM; Rohrbach JEC; Liu L; Benzohra A; Lesegretain A; Cortes J; Perl AE; Sekeres MA; Dombret H; Amadori S; Wang J; Levis MJ; Schlenk RF;
Lancet; 2023 May; 401(10388):1571-1583. PubMed ID: 37116523
[TBL] [Abstract][Full Text] [Related]
9. Quizartinib for the treatment of acute myeloid leukemia.
Garcia-Horton A; Yee KW
Expert Opin Pharmacother; 2020 Dec; 21(17):2077-2090. PubMed ID: 32772726
[TBL] [Abstract][Full Text] [Related]
10. Quizartinib, a selective FLT3 inhibitor, maintains antileukemic activity in preclinical models of RAS-mediated midostaurin-resistant acute myeloid leukemia cells.
Aikawa T; Togashi N; Iwanaga K; Okada H; Nishiya Y; Inoue S; Levis MJ; Isoyama T
Oncotarget; 2020 Mar; 11(11):943-955. PubMed ID: 32215183
[No Abstract] [Full Text] [Related]
11. Improved efficacy of quizartinib in combination therapy with PI3K inhibition in primary FLT3-ITD AML cells.
Darici S; Jørgensen HG; Huang X; Serafin V; Antolini L; Barozzi P; Luppi M; Forghieri F; Marmiroli S; Zavatti M
Adv Biol Regul; 2023 Aug; 89():100974. PubMed ID: 37245251
[TBL] [Abstract][Full Text] [Related]
12. The magnitude of CXCR4 signaling regulates resistance to quizartinib in FLT3/ITD
Fukuda S; Matsuda N; Shoji T; Onishi C; Hirade T; Taketani T; Pelus LM
Leuk Res; 2023 Jan; 124():106983. PubMed ID: 36473282
[TBL] [Abstract][Full Text] [Related]
13. Q-HAM: a multicenter upfront randomized phase II trial of quizartinib and high-dose Ara-C plus mitoxantrone in relapsed/refractory AML with FLT3-ITD.
Jaramillo S; Le Cornet L; Kratzmann M; Krisam J; Görner M; Hänel M; Röllig C; Wass M; Scholl S; Ringhoffer M; Reichart A; Steffen B; Kayser S; Mikesch JH; Schaefer-Eckart K; Schubert J; Geer T; Martin S; Kieser M; Sauer T; Kriegsmann K; Hundemer M; Serve H; Bornhäuser M; Müller-Tidow C; Schlenk RF
Trials; 2023 Sep; 24(1):591. PubMed ID: 37715270
[TBL] [Abstract][Full Text] [Related]
14. Quizartinib (AC220) is a potent second generation class III tyrosine kinase inhibitor that displays a distinct inhibition profile against mutant-FLT3, -PDGFRA and -KIT isoforms.
Kampa-Schittenhelm KM; Heinrich MC; Akmut F; Döhner H; Döhner K; Schittenhelm MM
Mol Cancer; 2013 Mar; 12():19. PubMed ID: 23497317
[TBL] [Abstract][Full Text] [Related]
15. Homoharringtonine synergizes with quizartinib in FLT3-ITD acute myeloid leukemia by targeting FLT3-AKT-c-Myc pathway.
Wang F; Huang J; Guo T; Zheng Y; Zhang L; Zhang D; Wang F; Naren D; Cui Y; Liu X; Qu Y; Luo H; Yang Y; Wei H; Guo Y
Biochem Pharmacol; 2021 Jun; 188():114538. PubMed ID: 33831397
[TBL] [Abstract][Full Text] [Related]
16. The Flt3-inhibitor quizartinib augments apoptosis and promotes maladaptive remodeling after myocardial infarction in mice.
Monogiou Belik D; Bernasconi R; Xu L; Della Verde G; Lorenz V; Grüterich V; Balzarolo M; Mochizuki M; Pfister O; Kuster GM
Apoptosis; 2024 Apr; 29(3-4):357-371. PubMed ID: 37945814
[TBL] [Abstract][Full Text] [Related]
17. Practical Considerations for Treatment of Relapsed/Refractory FLT3-ITD Acute Myeloid Leukaemia with Quizartinib: Illustrative Case Reports.
Martínez-Cuadrón D; Rodríguez-Macías G; Rodríguez-Veiga R; Boluda B; Montesinos P
Clin Drug Investig; 2020 Mar; 40(3):227-235. PubMed ID: 31912423
[TBL] [Abstract][Full Text] [Related]
18. Quizartinib, an FLT3 inhibitor, as monotherapy in patients with relapsed or refractory acute myeloid leukaemia: an open-label, multicentre, single-arm, phase 2 trial.
Cortes J; Perl AE; Döhner H; Kantarjian H; Martinelli G; Kovacsovics T; Rousselot P; Steffen B; Dombret H; Estey E; Strickland S; Altman JK; Baldus CD; Burnett A; Krämer A; Russell N; Shah NP; Smith CC; Wang ES; Ifrah N; Gammon G; Trone D; Lazzaretto D; Levis M
Lancet Oncol; 2018 Jul; 19(7):889-903. PubMed ID: 29859851
[TBL] [Abstract][Full Text] [Related]
19. The role of quizartinib in the treatment of acute myeloid leukemia.
Ostronoff F; Estey E
Expert Opin Investig Drugs; 2013 Dec; 22(12):1659-69. PubMed ID: 24070241
[TBL] [Abstract][Full Text] [Related]
20. Dasatinib overcomes stroma-based resistance to the FLT3 inhibitor quizartinib using multiple mechanisms.
Patel AB; Pomicter AD; Yan D; Eiring AM; Antelope O; Schumacher JA; Kelley TW; Tantravahi SK; Kovacsovics TJ; Shami PJ; O'Hare T; Deininger MW
Leukemia; 2020 Nov; 34(11):2981-2991. PubMed ID: 32409689
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
